Brokerages expect CorMedix Inc (NASDAQ:CRMD) to announce sales of $190,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for CorMedix’s earnings, with the highest sales estimate coming in at $300,000.00 and the lowest estimate coming in at $80,000.00. CorMedix reported sales of $370,000.00 during the same quarter last year, which indicates a negative year over year growth rate of 48.6%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 13th.
According to Zacks, analysts expect that CorMedix will report full-year sales of $460,000.00 for the current financial year, with estimates ranging from $430,000.00 to $490,000.00. For the next financial year, analysts expect that the firm will report sales of $12.28 million, with estimates ranging from $9.89 million to $14.67 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover CorMedix.
Shares of CRMD stock traded down $0.04 on Monday, reaching $8.16. 999 shares of the company’s stock were exchanged, compared to its average volume of 492,207. The company’s fifty day simple moving average is $8.82 and its 200 day simple moving average is $6.57. CorMedix has a 52 week low of $1.90 and a 52 week high of $13.70.
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Further Reading: How to Track your Portfolio in Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.